3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
pembrolizumab
20
Bevacizumab
14
Carboplatin
12
Standard of Care
10
Nivolumab
9
Cyclophosphamide
9
Cetuximab
8
Pemetrexed
7
Exercise
7
Doxorubicin
7
durvalumab
6
atezolizumab
6
Temozolomide
6
Radiotherapy
6
Prednisone
6
Paclitaxel
6
Cisplatin
6
Blood Specimen Collection
6
abemaciclib
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
olaparib
4
dostarlimab
4
Rituximab
4
Leucovorin
4
Gemcitabine
4
Fulvestrant
4
Docetaxel
4
Dexamethasone
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
enfortumab vedotin
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled